Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · IEX Real-Time Price · USD
53.75
+0.45 (0.84%)
May 16, 2024, 4:00 PM EDT - Market closed
Company Description
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Apogee Therapeutics, Inc.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Michael Thomas Henderson M.D. |
Contact Details
Address: 221 Crescent St., Building 17, Suite 102b Waltham, Massachusetts 02453 United States | |
| Phone | 650-394-5230 |
| Website | apogeetherapeutics.com |
Stock Details
| Ticker Symbol | APGE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001974640 |
| CUSIP Number | 03770N101 |
| ISIN Number | US03770N1019 |
| Employer ID | 93-4958665 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Thomas Henderson M.D. | Chief Executive Officer and Director |
| Jane Pritchett V. Henderson | Chief Financial Officer |
| Dr. Carl Linden Dambkowski M.D. | Chief Medical Officer |
| Dr. Rebecca Dabora Ph.D. | Chief Technical Officer |
| Noel Kurdi | Vice President of Investor Relations |
| Matthew Batters J.D. | General Counsel |
| Emily Cox | Vice President and Head of People |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations |
| Dr. Drew Badger Ph.D. | Senior Vice President and Head of Regulatory Affairs and Toxicology |
| Monica Forbes | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2024 | 8-K | Current Report |
| May 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 11, 2024 | 424B4 | Prospectus |